Last reviewed · How we verify
NCT04018521
Use of Parent Connectors in First Episode Psychosis (FEP)
NA trial testing PPN in First Episode Psychosis (FEP). Withdrawn.
23 February 2022
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Start date | 1 August 2021 |
| Primary completion | 23 February 2022 |
| Estimated completion | 23 February 2022 |
Drugs / interventions tested
- PPN
- CSC Usual Care
Conditions studied
- First Episode Psychosis (FEP) — all drugs for First Episode Psychosis (FEP) →
Sponsor
NYU Langone Health — full company profile →
Who can join
Adults 21 to 100, any sex, with First Episode Psychosis (FEP). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study proposes to adapt an evidence based peer parent navigator (PPN) intervention, called Parent Connectors, in which trained and supervised PPNs deliver weekly telephone-based support for six to nine months to parents or caregivers of all newly enrolled youth or young adults (Y/YA) in FEP services. This PPN model will be used to enhance the delivery of Coordinated Specialty Care (CSC) for Y/YA in New York's state program for FEP, called OnTrackNY (OTNY). This research project has potential to add value to the CSC model through the inclusion of a feasible, low burden intervention that may improve family participation in services and Y/YA outcomes. Using random assignment, this study will examine the feasibility and preliminary impact of an accelerator strategy-the inclusion of peer parent navigators or PPNs-in CSC teams.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Parenting interventions for people with schizophrenia or related serious mental illness.
Radley J, Grant C, Barlow J, Johns L. · · 2021 · cited 8× · PMID 34666417 · DOI 10.1002/14651858.cd013536.pub2
Verify or expand the search:
- PubMed search for NCT04018521
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PPN
Trials testing the same drug.
- NCT06881069 — Reach Through Equitable Implementation in Utah · NA · recruiting
Other recruiting trials for First Episode Psychosis (FEP)
Currently open trials in the same condition.
- NCT06650943 — Nursing Intervention in Weight and Metabolic Syndrome Management in First-episode Psychosis (MetaKOP) · NA · recruiting
- NCT06634446 — Self-administered COgnitive Personalized Training in Early Psychosis · NA · recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04018521 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 4 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04018521.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing